8-K: CalciMedica Announces Positive Phase 2b Trial Results for Auxora in Acute Pancreatitis

CalciMedica's Auxora demonstrates significant efficacy in treating acute pancreatitis with systemic inflammatory response syndrome, showing substantial reductions in respiratory failure and hospital stays.

Summary

• CalciMedica announced positive results from its Phase 2b CARPO trial of Auxora for acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS).
• The trial met its objective by showing clinically meaningful reductions in key endpoints for patients receiving high and medium doses of Auxora compared to placebo or combined placebo and low dose Auxora.
• The study enrolled 216 patients, randomized into four groups receiving either high (2.0 mg/kg), medium (1.0 mg/kg), or low (0.5 mg/kg) doses of Auxora or a placebo.
• The trial demonstrated a 100% relative risk reduction in new-onset severe respiratory failure and a 64.2% relative risk reduction in new-onset persistent respiratory failure when combining high and medium dose patients compared to combined low dose and placebo patients.
• High dose Auxora patients experienced a 20% relative risk reduction in new-onset necrotizing pancreatitis compared to placebo patients.
• The median time to medically indicated discharge was reduced by 15 hours for high dose Auxora patients compared to placebo.
• A win ratio analysis showed that the high dose of Auxora outperformed placebo with a stratified win ratio of 1.640 (p = 0.0372).
• There were no drug-related treatment emergent serious adverse events or deaths in patients receiving the high dose of Auxora.

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 2b trial, with statistically significant improvements in key endpoints and no drug-related serious adverse events in the high dose group. The company is moving towards a Phase 3 trial, indicating strong confidence in the drug's potential.

Positives

• Auxora demonstrated a statistically significant 100% reduction in new-onset severe respiratory failure in combined high and medium dose patients compared to combined low dose and placebo patients.
• There was a 64.2% relative risk reduction in new-onset persistent respiratory failure in combined high and medium dose patients compared to combined low dose and placebo patients.
• High dose Auxora showed a 20% relative risk reduction in new-onset necrotizing pancreatitis compared to placebo.
• The high dose of Auxora reduced the median time to medically indicated discharge by 15 hours compared to placebo.
• The win ratio analysis showed a statistically significant 1.640 win ratio for the high dose of Auxora compared to placebo.
• Auxora was well-tolerated, with no drug-related serious adverse events or deaths in the high dose group.
• The company has identified the most effective dose of Auxora for AP patients.
• The results suggest Auxora may minimize patient mortality and morbidity as well as the economic burden of AP.

Negatives

• The placebo group had approximately 12% lower proportion of hyper-inflamed patients than the study overall, which could have influenced the results.
• New onset necrotizing pancreatitis occurred in 29.7% of high dose patients, 40.8% of medium dose patients, 38.6% of low dose patients, and 37.0% of placebo patients, indicating that the medium and low doses did not perform better than placebo.

Risks

• The company's expectations and beliefs regarding the potential benefits of Auxora may not materialize.
• Actual outcomes and results may differ materially from those contemplated by forward-looking statements due to various uncertainties and risks.
• There are risks related to obtaining and maintaining regulatory approval for Auxora.
• Results from clinical trials may not be indicative of future results.
• There are potential safety and other complications from Auxora.
• The company faces risks related to the scope, progress, and expansion of developing and commercializing Auxora.
• The company's ability to protect its intellectual property position is a risk.
• The company's financial position and need for additional capital are risks.

Future Outlook

CalciMedica is planning for a Phase 3 program of Auxora in patients with AP with accompanying SIRS, pending an end-of-Phase 2 meeting with the FDA. The company also expects to read out data from the Phase 2 KOURAGE trial in AKI patients with respiratory failure in 2025 and the Phase 1/2 CRSPA trial in pediatric patients with AIPT in 2025.

Management Comments

• Prof. Robert Sutton stated that Auxora continues to deliver across key AP endpoints, showing that the drug substantially reduced respiratory failure, necrotizing pancreatitis, and long hospital stays.
• Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica, noted that the CARPO results highlight Auxora's unique immunomodulatory action coupled with direct organ tissue protection.
• Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica, stated that they believe they have identified the most effective dose of Auxora for AP patients and have clarified how best to measure the drug's benefit.

Industry Context

The announcement is significant as there are currently no approved therapies for acute pancreatitis, highlighting a substantial unmet medical need. The positive results for Auxora position it as a potential new treatment option in a critical illness with limited therapeutic options.

Comparison to Industry Standards

• The results of the CARPO trial are compared to previous Phase 2 trials of Auxora in other acute critical diseases, showing consistent positive results.
• The reduction in respiratory failure is particularly significant as it is a major driver of mortality in AP patients, and there are no approved therapies for this condition.
• The win ratio analysis provides a comprehensive evaluation of Auxora's benefits, which is a more robust measure than looking at individual endpoints in isolation.
• The company is comparing the results to the standard of care, which is primarily supportive care, and demonstrating that Auxora provides a significant improvement over this.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients with acute pancreatitis and SIRS may benefit from a new treatment option.
• Healthcare systems may see reduced costs due to shorter hospital stays and reduced complications.
• Employees of CalciMedica may be positively impacted by the company's progress.

Next Steps

• CalciMedica plans to have an end-of-Phase 2 meeting with the FDA to discuss the design of a Phase 3 trial of Auxora in patients with AP with accompanying SIRS.
• The company will continue its Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with associated acute hypoxemic respiratory failure, with data expected in 2025.
• The company will continue to support the ongoing Phase 1/2 CRSPA trial of Auxora in patients with asparaginase-induced pancreatic toxicity (AIPT), with data expected in 2025.

Key Dates

Keywords

Auxora, Acute Pancreatitis, Systemic Inflammatory Response Syndrome, Respiratory Failure, Clinical Trial, Phase 2b, CARPO, Necrotizing Pancreatitis, CRAC Channel Inhibitor, FDA